Media inquiries only, please contact Andrea Hofelich via email or phone, 202-827-2078.
National Pharmaceutical Council and Duke-Margolis Center for Health Policy Announce New Health Policy Fellow ( )
The National Pharmaceutical Council and Duke University's Robert J. Margolis, MD, Center for Health Policy announced that Taruja Karmarkar, PhD, has been named the 2018-20 post-doctoral health policy fellow.
Study of U.S. Commercial Health Plans Shows Widespread Variation in Coverage and Reimbursement for Specialty Medicines ( )
(July 9, 2018, Washington, DC)—A new study published in the July issue of Health Affairs shows that insurance coverage and reimbursement for specialty medications var
Survey research, published in the Journal of Managed Care & Specialty Pharmacy, notes the substantial impact that biopharmaceutical innovation has had on health outcomes, particularly in the treatment of HIV, chronic obstructive pulmonary disease (COPD) and depression.
The National Pharmaceutical Council, a health policy research organization based in Washington, D.C., today welcomed four biopharmaceutical companies to its growing membership roster. They include AstraZeneca, Gilead Sciences, Horizon Pharma plc. and Spark Therapeutics, Inc.
National Pharmaceutical Council Launches Going Below the Surface, a Research Initiative to Explore the Different Dimensions of Health Care Spending ( )
The National Pharmaceutical Council launched Going Below the Surface—a new research-first initiative intended to engage stakeholders across the health care ecosystem in conversation about what’s driving health care spending in the United States and how we can spend more effectively.
NPC announced that Mark J. Nagy, Vice President, Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, has been elected chairman of NPC’s Board of Directors for 2017-2018. NPC’s Board of Directors also elected other members to its executive committee.